Overview
Focal dermal hypoplasia (FDH), also known as Goltz syndrome or Goltz-Gorlin syndrome, is a rare multisystem genetic disorder primarily affecting the skin, skeletal system, eyes, and face. It is caused by mutations in the PORCN gene, which plays a critical role in Wnt signaling pathways essential for embryonic development. The condition predominantly affects females, as it is typically lethal in males, though rare affected males have been reported (often attributed to somatic mosaicism or Klinefelter syndrome). The hallmark feature of FDH is patchy, thin skin (dermal hypoplasia) with areas where fat tissue herniates through the skin, creating soft yellowish nodules. Skin findings often follow the lines of Blaschko and may include linear streaks of hypo- or hyperpigmentation, telangiectasias, and raspberry-like papillomas of the skin and mucous membranes. Skeletal abnormalities are common and include syndactyly (fusion of fingers or toes), oligodactyly (missing digits), split hand/foot malformation, and limb asymmetry. Ocular manifestations may include colobomas, microphthalmia, and strabismus. Dental anomalies such as enamel hypoplasia, oligodontia, and malocclusion are frequently observed. Additional features can include nail dystrophy, sparse or brittle hair, and occasionally involvement of the kidneys, heart, or gastrointestinal tract. There is no cure for focal dermal hypoplasia, and management is supportive and multidisciplinary. Treatment is tailored to the individual's specific manifestations and may include surgical correction of skeletal anomalies, dermatologic management of skin lesions (including removal of papillomas if symptomatic), ophthalmologic care, dental interventions, and physical or occupational therapy. Regular monitoring by a team including geneticists, dermatologists, orthopedic surgeons, ophthalmologists, and dentists is recommended to address the wide spectrum of potential complications.
Also known as:
Clinical phenotype terms— hover any for plain English:
X-linked dominant
Carried on the X chromosome; a single copy can cause the condition
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventBaylor College of Medicine
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Focal dermal hypoplasia.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Focal dermal hypoplasia.
Community
No community posts yet. Be the first to share your experience with Focal dermal hypoplasia.
Start the conversation →Latest news about Focal dermal hypoplasia
No recent news articles for Focal dermal hypoplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Focal dermal hypoplasia
What is Focal dermal hypoplasia?
Focal dermal hypoplasia (FDH), also known as Goltz syndrome or Goltz-Gorlin syndrome, is a rare multisystem genetic disorder primarily affecting the skin, skeletal system, eyes, and face. It is caused by mutations in the PORCN gene, which plays a critical role in Wnt signaling pathways essential for embryonic development. The condition predominantly affects females, as it is typically lethal in males, though rare affected males have been reported (often attributed to somatic mosaicism or Klinefelter syndrome). The hallmark feature of FDH is patchy, thin skin (dermal hypoplasia) with areas whe
How is Focal dermal hypoplasia inherited?
Focal dermal hypoplasia follows a x-linked dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Focal dermal hypoplasia typically begin?
Typical onset of Focal dermal hypoplasia is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Focal dermal hypoplasia?
Yes — 1 recruiting clinical trial is currently listed for Focal dermal hypoplasia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Focal dermal hypoplasia?
17 specialists and care centers treating Focal dermal hypoplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.